Brief: Erytech Pharma Announces Positive Results From Eryaspase Phase 2 Trial

Phaxiam Therapeutics SA

07/12/2020 07:20

Dec 7 (Reuters) - ERYTECH PHARMA SA  ERYP.PA :
    * ANNOUNCES POSITIVE RESULTS FROM ERYASPASE PHASE 2 TRIAL IN
ACUTE
LYMPHOBLASTIC LEUKEMIA PRESENTED AT THE AMERICAN SOCIETY OF
HEMATOLOGY ANNUAL MEETING
    * THE STUDY CONFIRMS THE POTENTIAL OF ERYASPASE AS AN
ATTRACTIVE
TREATMENT OPTION FOR ALL PATIENTS WITH HYPERSENSITIVITY TO
PEG-ASPARAGINASE
    * PRIMARY OBJECTIVES OF THE TRIAL WERE ASPARAGINASE ENZYME
ACTIVITY AND SAFETY. BOTH ENDPOINTS WERE MET

Source text for Eikon:  ID:nGNX4BRYgr 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))